FDA Approves Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia
Jul 20
2018
The U.S. Food and Drug Administration approved ivosidenib (Tibsovo, Agios Pharmaceuticals, Inc.) for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
